Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
BMC Cancer Jan 20, 2018
Hollis RL, et al. - Researchers aim to determine whether BRCA1/2 status influences the response rate to single-agent pegylated liposomal doxorubicin (PLD) in high grade serous (HGS) ovarian carcinomas (OC). As per findings, HGS OC patients with BRCA1/2 variants prognosticated damaging to protein function experience superior sensitivity to PLD, consistent with impaired DNA repair.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
